Rallybio RLYB Stock
Rallybio Price Chart
Rallybio RLYB Financial and Trading Overview
| Rallybio stock price | 0.3 USD |
| Previous Close | 7.73 USD |
| Open | 7.7 USD |
| Bid | 0 USD x 1200 |
| Ask | 0 USD x 900 |
| Day's Range | 7.3 - 7.84 USD |
| 52 Week Range | 4.15 - 15.89 USD |
| Volume | 77.9K USD |
| Avg. Volume | 55K USD |
| Market Cap | 278.2M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.33 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.33 USD |
RLYB Valuation Measures
| Enterprise Value | 141.92M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.2901785 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.7923151 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.977 |
Trading Information
Rallybio Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 2.36% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15.89 USD |
| 52 Week Low | 4.15 USD |
| 50-Day Moving Average | 6.01 USD |
| 200-Day Moving Average | 7.39 USD |
RLYB Share Statistics
| Avg. Volume (3 month) | 55K USD |
| Avg. Daily Volume (10-Days) | 103.2K USD |
| Shares Outstanding | 37.75M |
| Float | 14.73M |
| Short Ratio | 23.13 |
| % Held by Insiders | 6.12% |
| % Held by Institutions | 87.85% |
| Shares Short | 936.25K |
| Short % of Float | 2.94% |
| Short % of Shares Outstanding | 2.47% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.11% |
| Return on Equity (ttm) | -43.66% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -71776000 USD |
| Net Income Avi to Common (ttm) | -69474000 USD |
| Diluted EPS (ttm) | -1.97 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 150.39M USD |
| Total Cash Per Share (mrq) | 3.98 USD |
| Total Debt (mrq) | 518K USD |
| Total Debt/Equity (mrq) | 0.33 USD |
| Current Ratio (mrq) | 23.717 |
| Book Value Per Share (mrq) | 4.112 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -62318000 USD |
| Levered Free Cash Flow (ttm) | -37889500 USD |
Profile of Rallybio
| Country | United States |
| State | CT |
| City | New Haven |
| Address | 234 Church Street |
| ZIP | 06510 |
| Phone | 203 859 3820 |
| Website | https://www.rallybio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 43 |
Rallybio Corporation, a clinical-stage biotechnology company, engages in identifying, accelerating, and development of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Q&A For Rallybio Stock
What is a current RLYB stock price?
Rallybio RLYB stock price today per share is 0.3 USD.
How to purchase Rallybio stock?
You can buy RLYB shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Rallybio?
The stock symbol or ticker of Rallybio is RLYB.
Which industry does the Rallybio company belong to?
The Rallybio industry is Biotechnology.
How many shares does Rallybio have in circulation?
The max supply of Rallybio shares is 41.61M.
What is Rallybio Price to Earnings Ratio (PE Ratio)?
Rallybio PE Ratio is now.
What was Rallybio earnings per share over the trailing 12 months (TTM)?
Rallybio EPS is -1.33 USD over the trailing 12 months.
Which sector does the Rallybio company belong to?
The Rallybio sector is Healthcare.
Rallybio RLYB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8504.39 USD — |
+1.34
|
— — | 8367.19 USD — | 8515.13 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
- {{ link.label }} {{link}}